GRPH Graphite Bio, Inc.

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.

$2.82
As of 06/24/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/15/2009
Outstanding shares:  57,970,110
Average volume:  771,327
Market cap:   $154,780,194
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BP7L2W6

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.45
PS ratio:   0.00
Return on equity:   -21.28%
Net income %:   0.00%